AU3806699A - Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy - Google Patents

Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy

Info

Publication number
AU3806699A
AU3806699A AU38066/99A AU3806699A AU3806699A AU 3806699 A AU3806699 A AU 3806699A AU 38066/99 A AU38066/99 A AU 38066/99A AU 3806699 A AU3806699 A AU 3806699A AU 3806699 A AU3806699 A AU 3806699A
Authority
AU
Australia
Prior art keywords
amf
conjugates
ligand
cancer therapy
cytotoxic molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38066/99A
Inventor
Ivan R Nabi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Publication of AU3806699A publication Critical patent/AU3806699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU38066/99A 1998-05-22 1999-05-13 Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy Abandoned AU3806699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002238257A CA2238257A1 (en) 1998-05-22 1998-05-22 Endocytosis of amf-r and uses thereof in cancer therapy
CA2238257 1998-05-22
PCT/CA1999/000438 WO1999061060A1 (en) 1998-05-22 1999-05-13 Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy

Publications (1)

Publication Number Publication Date
AU3806699A true AU3806699A (en) 1999-12-13

Family

ID=4162458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38066/99A Abandoned AU3806699A (en) 1998-05-22 1999-05-13 Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy

Country Status (3)

Country Link
AU (1) AU3806699A (en)
CA (2) CA2238257A1 (en)
WO (1) WO1999061060A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074897A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Protein amf-1 to amf-10 and nucleic acids encoding the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362278A4 (en) * 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US5728383A (en) * 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5382521A (en) * 1992-07-14 1995-01-17 Michigan Cancer Foundation Method of determining metastatic potential of bladder tumor cells
DE69734887T2 (en) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla TUMOR FINDING MOLECULES, DIVIDING CONJUGATES, AND METHOD FOR USE THEREOF
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
CA2238257A1 (en) 1999-11-22
WO1999061060A1 (en) 1999-12-02
CA2333021A1 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
AU2437000A (en) Anti-cd3 immunotoxins and therapeutic uses therefor
AU5536196A (en) Cancer diagnosis and therapy based on mutations in tgf-beta receptors
AU3117697A (en) Radiolabeled fusion toxins for cancer therapy
AU5089799A (en) Drug complex for treatment of metastatic prostate cancer
EE9900179A (en) Use of conjugates in prostate cancer drugs
IL157993A0 (en) Molecular conjugates for use in cancer treatment and methods for the preparation thereof
AU7320394A (en) Pro-cytotoxic drug conjugates for anticancer therapy
AU8695698A (en) Pharmacologic drug combination in vagal-induced asystole
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
AU1190901A (en) Replication selective adenoviruses for use in cancer therapy
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
AU4268496A (en) Targeting complexes and use thereof
AU2001292797A1 (en) Metal complexes for use in medical and therapeutic applications
AU3806699A (en) Conjugates of an amf ligand and a cytotoxic molecule for use in cancer therapy
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU4563097A (en) Cancer therapy using an oncogene product and a foreign mhc molecule
IL133536A0 (en) 6-pyrrolidin-2-ylpyridine derivatives, their preparation and application in therapy
AU3582995A (en) Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer
AU3349997A (en) Reg gene expression in cancer tissue
AU9358398A (en) Use of p-glycoprotein (pgp) inhibitors in the treatment of cancer
AU2002228085A1 (en) Utilization of a claudin-4 ligand and conjugates thereof in the therapy and diagnosis of tumors
AU7996800A (en) Diagnostic and therapeutic uses for a gene differentially expressed in prostate cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase